26^th International Conference on Cancer and Oncology

A research team led by researchers from the University of Kansas and KU Cancer Center has developed a device which could detect cancer in a minuscule amount of blood or blood component. The device, which is called a “3D nano-patterned chip”, identifies and diagnoses cancer by filtering for exosomes, pushing them to meet the surface of the ship for analysis. Exosomes help in sending messages to the  recipient cells and communicating molecular information important in many biological functions. In the case of cancerous cells, these contain biological information that can direct tumor growth and spread in case of cancerous cells. Basically, tumors send out exosomes packaging active molecules that mirror the biological features of the parental cells. While all cells produce exosomes, tumor cells are active compared to normal cells. To test the chip’s effectiveness, the researchers used clinical samples from patients suffering from ovarian cancer, a type of cancer ...

A recent clinical trial the study has suggested that the anti-cancer drug Revlimid, also called Lenalidomide, may slow down the progression of smoldering myeloma into multiple myeloma. Revlimid is already used to treat multiple myeloma. The study revealed that individuals who received Revlimid had a reduced risk of developing multiple myeloma with initial 3 years than the individuals who were under the observation of developing the disease for the same period. Myeloma is caused by abnormal growth of plasma cells in the bone marrow. Plasma cells are a type of white blood cells in the bone marrow. Bones, immune system, kidneys, and red blood cell count are get affected by this disease. Smoldering myeloma is a pre-diseased condition in which certain proteins in the blood cause plasma cells to grow abnormally in the bone marrow. Though it does not show any symptoms of disease, however about half of the individuals diagnosed with the condition develop multiple myeloma within 5 year...